From the Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, Italy.
Prog Cardiovasc Dis. 2017 Nov-Dec;60(3):370-385. doi: 10.1016/j.pcad.2017.10.005. Epub 2017 Nov 9.
Mitral regurgitation (MR) is the one of the most frequent valvular heart diseases in the developed world, often requiring surgical correction. Degenerative MR is the most common type of non-ischemic, organic MR in the western world. Since no medical treatment has been shown to be effective in preventing the consequences of volume overload in asymptomatic degenerative MR, risk stratification is essential. Currently, this is achieved using clinical and precisely quantified echocardiographic parameters, with newer technologies like cardiac magnetic resonance gaining increasing prominence. While surgical mitral repair, often performed using minimally invasive/robotic techniques, is the current gold-standard for definitive therapeutic management, there is rapid emergence of percutaneous techniques for mitral valve repair/replacement in cases of degenerative MR. This state-of-the-art-review will discuss the latest knowledge in the natural history, imaging, surgical and percutaneous therapies in patients with degenerative MR.
二尖瓣反流(MR)是发达国家最常见的瓣膜性心脏病之一,通常需要手术矫正。退行性 MR 是西方世界最常见的非缺血性、器质性 MR 类型。由于没有医学治疗被证明可以有效预防无症状退行性 MR 容量超负荷的后果,因此风险分层至关重要。目前,这是通过使用临床和精确量化的超声心动图参数来实现的,而心脏磁共振等新技术的作用日益凸显。虽然二尖瓣修复术(通常采用微创/机器人技术进行)是退行性 MR 确定性治疗管理的当前金标准,但在退行性 MR 病例中,经皮二尖瓣修复/置换技术正在迅速出现。这篇最新综述将讨论退行性 MR 患者的自然史、影像学、手术和经皮治疗方面的最新知识。